We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+64.7%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$229M
AUM Growth
-$15.5M
Cap. Flow
-$102M
Cap. Flow %
-44.43%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$38.3M
2
RVMD icon
Revolution Medicines
RVMD
+$33M
3
NRIX icon
Nurix Therapeutics
NRIX
+$24.4M
4
VYGR icon
Voyager Therapeutics
VYGR
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
1
Pliant Therapeutics
PLRX
$65M
$80.2M 35.02%
3,839,160
-2,000,000
-34% -$38.3M
RVMD icon
2
Revolution Medicines
RVMD
$42.1B
$71.1M 31.03%
3,604,130
-1,500,000
-29% -$33M
VYGR icon
3
Voyager Therapeutics
VYGR
$189M
$32.1M 14.03%
5,428,933
-962,243
-15% -$6.16M
FULC icon
4
Fulcrum Therapeutics
FULC
$288M
$32.1M 14%
3,962,202
– –
DBTX
5
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$10.9M 4.74%
3,139,685
– –
JNCE
6
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.69M 1.17%
1,148,780
– –
NRIX icon
7
Nurix Therapeutics
NRIX
$2.62B
– –
-1,922,549
Closed -$24.4M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q3 2022 Portfolio in Review

As of Q3 2022, TRV GP III held 7 positions worth $229M, down 6.3% from $244M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $102M in Q3 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Nurix Therapeutics, an estimated $24.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q3 2022 reduction was Pliant Therapeutics, cutting an estimated $38.3M.
  • TRV GP III fully exited Nurix Therapeutics in Q3 2022, selling an estimated $24.4M.
  • TRV GP III's ten largest holdings make up 100% of its $229M portfolio in Q3 2022.
  • TRV GP III opened 0 new positions and closed 1 in Q3 2022.
  • TRV GP III's portfolio value fell 6.3% quarter-over-quarter to $229M.

Based on TRV GP III's 13F filing for Q3 2022, filed 3 Nov 2022.